The sole question on appeal was whether it would have been obvious to make zolmitriptan into a nasal spray. The Federal Circuit agreed with the district court that the prior art taught away from formulating zolmitriptan for intranasal administration.
The post Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious appeared first on IPWatchdog.com | Patents & Patent Law.
Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- Supreme Court Ponders Proper Application of the Computer Fraud and Abuse Act
- A Swing (and a Miss) at NIH Tech Transfer
- Thought Experiment: Is Our Patent System Ready for a Potential Future of Brain Interfacing?
- How Patents Helped Sprout the World’s First Plantable Pencil
- Cybergenetics Appeals Ohio Federal Judge Ruling that Alice Kills DNA Analysis Patents
Recent Posts
- Supreme Court Ponders Proper Application of the Computer Fraud and Abuse Act
- A Swing (and a Miss) at NIH Tech Transfer
- Thought Experiment: Is Our Patent System Ready for a Potential Future of Brain Interfacing?
- How Patents Helped Sprout the World’s First Plantable Pencil
- Cybergenetics Appeals Ohio Federal Judge Ruling that Alice Kills DNA Analysis Patents